ReviewFrontiers in oncology2026
Expert recommendations on the management of major and minor toxicities associated with the use of lorlatinib in Latin America.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) that has been shown to have high efficacy in the first line setting for treatment of advanced ALK-rearranged non-small cell lung cancer (NSCLC). However, some adverse events have been described that require proper follow-up and management to obtain the maximum benefit from treatment and minimize risk to the patient. These include dyslipidemia and weight gain, conditions that in Latin America have a high prevalence in the general population, which coupled with limitations in timely access to specialized care, could influence both manifestation and management. The objective of this consensus is to provide recommendations tailored to our real-world setting that will optimize the monitoring and early management of toxicities in patients treated with lorlatinib in Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.